Insider Selling: Phreesia, Inc. (NYSE:PHR) Director Sells 7,431 Shares of Stock

Phreesia, Inc. (NYSE:PHR - Get Free Report) Director Michael Weintraub sold 7,431 shares of the company's stock in a transaction dated Monday, June 9th. The stock was sold at an average price of $27.51, for a total transaction of $204,426.81. Following the completion of the transaction, the director now owns 143,039 shares in the company, valued at approximately $3,935,002.89. The trade was a 4.94% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Michael Weintraub also recently made the following trade(s):

• On Tuesday, June 10th, Michael Weintraub sold 2,569 shares of Phreesia stock. The stock was sold at an average price of $27.86, for a total value of $71,572.34.

Phreesia Trading Down 2.4%

PHR traded down $0.64 during trading on Friday, reaching $25.99. The company had a trading volume of 448,368 shares, compared to its average volume of 443,599. The stock has a market cap of $1.55 billion, a P/E ratio of -17.68 and a beta of 0.68. The business has a 50 day simple moving average of $25.01 and a 200-day simple moving average of $25.77. Phreesia, Inc. has a 52 week low of $17.07 and a 52 week high of $30.53. The company has a quick ratio of 1.74, a current ratio of 1.74 and a debt-to-equity ratio of 0.04.

Phreesia (NYSE:PHR - Get Free Report) last issued its quarterly earnings results on Wednesday, May 28th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.13) by $0.06. The company had revenue of $115.94 million during the quarter, compared to the consensus estimate of $115.00 million. Phreesia had a negative return on equity of 32.78% and a negative net margin of 20.43%. Phreesia's revenue was up 14.5% on a year-over-year basis. During the same period last year, the company earned ($0.05) earnings per share. On average, equities analysts anticipate that Phreesia, Inc. will post -1.1 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have recently commented on PHR. Truist Financial upped their price target on shares of Phreesia from $34.00 to $35.00 and gave the company a "buy" rating in a research report on Thursday, May 29th. Needham & Company LLC reaffirmed a "buy" rating and set a $29.00 price target on shares of Phreesia in a research report on Thursday, March 13th. Wall Street Zen raised shares of Phreesia from a "hold" rating to a "buy" rating in a research report on Sunday, June 1st. KeyCorp reduced their target price on shares of Phreesia from $30.00 to $28.00 and set an "overweight" rating for the company in a report on Wednesday, April 16th. Finally, DA Davidson reduced their target price on shares of Phreesia from $36.00 to $34.00 and set a "buy" rating for the company in a report on Monday, April 14th. Twelve analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of "Buy" and an average target price of $31.64.

Institutional Trading of Phreesia

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Rhumbline Advisers increased its stake in Phreesia by 3.8% in the first quarter. Rhumbline Advisers now owns 86,844 shares of the company's stock worth $2,220,000 after purchasing an additional 3,213 shares during the period. Strs Ohio purchased a new stake in Phreesia in the first quarter worth $271,000. Acadian Asset Management LLC increased its stake in Phreesia by 105.2% in the first quarter. Acadian Asset Management LLC now owns 225,317 shares of the company's stock worth $5,754,000 after purchasing an additional 115,527 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of Phreesia by 108.7% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,644,988 shares of the company's stock valued at $67,606,000 after buying an additional 1,377,904 shares during the period. Finally, Caxton Associates LLP purchased a new position in shares of Phreesia during the first quarter valued at $316,000. Hedge funds and other institutional investors own 92.10% of the company's stock.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.